



# Radiosynthesis of the tumor hypoxia marker [ $^{18}\text{F}$ ]TFMISO via $O$ -[ $^{18}\text{F}$ ]trifluoroethylation reveals a striking difference between trifluoroethyl tosylate and iodide in regiochemical reactivity toward oxygen nucleophiles

Makiko Suehiro<sup>a,\*</sup>, Guangbin Yang<sup>b</sup>, Geralda Torchon<sup>b</sup>, Ellen Ackerstaff<sup>a</sup>, John Humm<sup>a</sup>, Jason Koutcher<sup>a</sup>, Ouathek Ouerfelli<sup>b</sup>

<sup>a</sup> Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA

<sup>b</sup> Department of Organic Synthesis Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA

## ARTICLE INFO

### Article history:

Received 15 December 2010

Revised 8 February 2011

Accepted 15 February 2011

Available online 18 February 2011

### Keywords:

$^{18}\text{F}$ -labeled trifluoromisonidazole ([ $^{18}\text{F}$ ]TFMISO)

Bimodal MRI and PET hypoxia marker

2,2,2-[ $^{18}\text{F}$ ]trifluoroethyl tosylate

$O$ -[ $^{18}\text{F}$ ]trifluoroethylation

## ABSTRACT

The MRI hypoxia marker trifluoromisonidazole (TFMISO) [1-(2-nitro-1*H*-imidazol-1-yl)-3-(2,2,2-trifluoroethoxy)propan-2-ol] was successfully labeled with  $^{18}\text{F}$  to expand its role into a bimodal PET/MRI probe.  $^{18}\text{F}$ -Labeling was achieved via a three-step procedure in which 2,2,2-[ $^{18}\text{F}$ ]trifluoroethyl *p*-toluenesulfonate prepared by  $^{18}\text{F}$ - $^{19}\text{F}$  exchange served as the [ $^{18}\text{F}$ ]trifluoroethylating agent. The  $O$ -[ $^{18}\text{F}$ ]trifluoroethylation reaction proceeded efficiently to give the intermediate 1,2-epoxy-3-(2,2,2-[ $^{18}\text{F}$ ]trifluoroethoxy)propane, with approximately 60% of  $^{18}\text{F}$  incorporated from the tosylate precursor, which was condensed with 2-nitroimidazole to yield [ $^{18}\text{F}$ ]TFMISO. Approximately 40% of the [ $^{18}\text{F}$ ]trifluoroethyl tosylate precursor was converted into the final product. In stark contrast, 2,2,2-[ $^{18}\text{F}$ ]trifluoroethyl iodide failed to produce [ $^{18}\text{F}$ ]TFMISO, giving instead 1,1-[ $^{18}\text{F}$ ]difluoro-2-iodoethoxy and 1-[ $^{18}\text{F}$ ]fluoro-2-iodovinyl analogs of [ $^{18}\text{F}$ ]TFMISO. Thus, this investigation has identified 2,2,2-[ $^{18}\text{F}$ ]trifluoroethyl tosylate as an excellent [ $^{18}\text{F}$ ]trifluoroethylating agent, which can convert efficiently an alcohol into the corresponding [ $^{18}\text{F}$ ]trifluoroethyl ether.

© 2011 Published by Elsevier Ltd.

## 1. Introduction

Non-invasive imaging techniques such as magnetic resonance imaging (MRI) and positron emission tomography (PET) may be used to visualize the in vivo distribution of hypoxic regions within a tumor based on hypoxia-targeting tracers.<sup>1,2</sup> The extent of tumoral hypoxia provides information that may assist in predicting the response to cancer therapies.<sup>2,3</sup> In vivo MRI or PET imaging of hypoxia has also been suggested as a tool for determining radioresistant hypoxic sub-volumes within the tumor suitable for biologically-based intensity modulated radiotherapy (IMRT).<sup>4,5</sup> For PET hypoxia imaging, the most frequently employed radiotracers are 2-nitroimidazole analogs labeled with the positron emitter  $^{18}\text{F}$  such as [ $^{18}\text{F}$ ]FMISO [1-(2-nitroimidazolyl)-3-[ $^{18}\text{F}$ ]fluoro-2-propanol] and [ $^{18}\text{F}$ ]FAZA [1-(5-[ $^{18}\text{F}$ ]fluoro-5-deoxy- $\beta$ -D-arabinofuranosyl)-2-nitroimidazole]. Several tri- and hexa-fluoro-2-nitroimidazole analogs have been developed as hypoxia probes for MRI, the localization of which in the living body can be detected and traced by  $^{19}\text{F}$ -magnetic

resonance spectroscopy (MRS). These are being extensively tested and studied in animal tumor models and in humans.<sup>6–15</sup>

TFMISO [1-(2-nitro-1*H*-imidazol-1-yl)-3-(2,2,2-trifluoroethoxy)propan-2-ol] (**1**, Fig. 1), is an FMISO analog which has three magnetically equivalent  $^{19}\text{F}$  atoms in the molecule and was originally developed as a radiosensitizer for cancer radiation therapy.<sup>6–9</sup> Chapman et al., who studied the in vivo behavior of  $^{14}\text{C}$ -labeled TFMISO in EMT-6 tumor-bearing mice, suggested the potential of TFMISO as an in vivo hypoxia marker for MRI as well as for PET if  $^{18}\text{F}$ -labeling of TFMISO could be done<sup>16</sup>; the three  $^{19}\text{F}$  atoms of the  $\text{CF}_3$  group in the molecule make it possible to detect the compound by MRS from outside of the body, and [ $^{18}\text{F}$ ]TFMISO (**2**, Fig. 1) makes PET imaging feasible as well. The first in vivo  $^{19}\text{F}$ -MRS detection of TFMISO in a tumor was reported by




Figure 1. Chemical structures of TFMISO and [ $^{18}\text{F}$ ]TFMISO.

\* Corresponding author. Tel.: +1 212 639 2000; fax: +1 212 717 3010.

E-mail address: [msuehiro@usa.net](mailto:msuehiro@usa.net) (M. Suehiro).

Raleigh et al.<sup>17</sup> More recently, in vivo MR spectroscopic images of the TFMISO distribution have been acquired in two preclinical tumor models.<sup>18,19</sup> Labeling of the CF<sub>3</sub> group in TFMISO with <sup>18</sup>F transforms the MR spectroscopic imaging agent into a PET radio-tracer and, thus, TFMISO becomes a bimodal probe for <sup>19</sup>F-MRI as well as <sup>18</sup>F-PET.

It is well recognized that labeling of a trifluoroalkyl group in a complex molecule with <sup>18</sup>F is not easily achieved, and normally requires a multi-step procedure. In the past, <sup>18</sup>F-labeling of the trifluoroethyl moiety in oxaquazepam, a benzodiazepine receptor antagonist, has been achieved using 2,2,2-[<sup>18</sup>F]trifluoroethyl triflate, which was prepared via a three-step procedure.<sup>20</sup> The trifluoropropyl moiety of EF3, a hypoxia marker and a potential bimodal probe, has also been labeled with <sup>18</sup>F via a five-step method using [<sup>18</sup>F]-poly(hydrogen fluoride)pyridinium as the precursor.<sup>21</sup> Following the prior work reported in the literature, we attempted to label TFMISO with <sup>18</sup>F via four approaches. Through our evolving approaches, which frequently gave unexpected outcomes, we have discovered a novel and versatile method for <sup>18</sup>F-labeling of TFMISO.

## 2. Approaches


The first approach (Approach A, Scheme 1) is to convert a 2-halo-2,2-difluoroethoxy (XCF<sub>2</sub>CH<sub>2</sub>O–, X = Cl/Br) analog of TFMISO (**3**) into [<sup>18</sup>F]TFMISO (**2**) via halogen–<sup>18</sup>F exchange. This approach seemed like an ideal one because it is simple and can be done in one pot. In addition, this is a no-carrier-added method, which can produce the PET tracer with high specific activity. The second and third approaches are based on O-[<sup>18</sup>F]trifluoroethylation of an alcohol, glycidol or 3-chloro-1,2-propanediol, with

2,2,2-[<sup>18</sup>F]trifluoroethyl iodide (Approach B, Scheme 2) or 2,2,2-[<sup>18</sup>F]trifluoroethyl *p*-toluenesulfonate (Approach C, Scheme 3). The resulting [<sup>18</sup>F]trifluoroethyl ether intermediate is then reacted with 2-nitroimidazole to produce [<sup>18</sup>F]TFMISO (**2**). The trifluoroethylating agents, the iodide and the tosylate, are labeled via <sup>18</sup>F–<sup>19</sup>F exchange. The fourth approach (Approach D, Scheme 5) is designed to combine the second and third steps of Approach C, that is, O-[<sup>18</sup>F]trifluoroethylation of the alcohol and the reaction between [<sup>18</sup>F]trifluoroethyl ether intermediate and 2-nitroimidazole, into one-step by using 3-(2-nitroimidazolyl)-1,2-propanediol (**10**), the primary alcohol of which is the target of O-[<sup>18</sup>F]trifluoroethylation with 2,2,2-[<sup>18</sup>F]trifluoroethyl tosylate.


## 3. Results

### 3.1. Approach A (Scheme 1)

Analytical HPLC data of the Cl–<sup>18</sup>F substitution reaction showed that (a) after heating at 80–130 °C, most of the OH-protected ClCF<sub>2</sub>-precursor (**4**) was converted into a more hydrophilic compound and only a small portion of the precursor was left intact (Fig. 2a), and (b) after removal of the OH-protection, only a trace amount of [<sup>18</sup>F]TFMISO, the retention time of which agreed with that of authentic TFMISO by co-injection, was produced (Fig. 2b). The major unlabeled by-product was isolated by semi-preparative HPLC and was found to be the elimination product (**5**) (Scheme 1) by mass spectrometry and <sup>1</sup>H/<sup>19</sup>F NMR. <sup>1</sup>H NMR (CDCl<sub>3</sub>), δ 3.74 (dd, 5.5 Hz, 10.2 Hz, 1H), 3.85 (dd, 4.0 Hz, 10.2 Hz, 1H), 4.27 (m, 1H), 4.41 (dd, 7.9 Hz, 14.0 Hz), 4.74 (dd, 3.4 Hz, 14.0 Hz), 5.77 (dd, 3.2 Hz, 15.4 Hz, 1H), 7.15 (s, 1H), 7.21 (s, 1H); <sup>19</sup>F NMR (CDCl<sub>3</sub>), δ 98.67 (d, 80 Hz), 118.76 (d, 80 Hz); MS (ESI); 356 ([M+Na]<sup>+</sup>); 346




Scheme 1.



Scheme 2.


## Approach C




Scheme 3.

( $[\text{M}+\text{Cl}]^-$ ). The use of the OH-protected  $\text{BrCF}_2$ -precursor instead of **4** did not change the outcome. Compound **5** was also the major

product of the reaction between the  $\text{ClCF}_2$ -precursor and tetrabutylammonium fluoride.



**Figure 2a.** HPLC analysis of a reaction between the OH-protected  $\text{ClCF}_2$ -precursor (**4**, Approach A) with  $\text{K}^{18}\text{F}$ /Kryptofix in DMF after heating at  $150^\circ\text{C}$  for 10 min. The analytical HPLC was performed using a C18 column and a mobile phase of acetonitrile–water (40/60) at a flow rate of 2 mL/min (for details see Section 6.1). Compound **4**, which is a mixture of two diastereomers, appears as a double peak in the HPLC chromatogram. The major product of the reaction, which appears as a double peak at a retention time of approximately 5 min, is also a mixture of two diastereomers (see Scheme 1). (Vertical axes are in arbitrary units.)




**Figure 2b.** HPLC analysis of the reaction mixture co-injected with authentic TFMISO after removal of the OH-protection group. The analytical HPLC was performed using a C18 column and a mobile phase of acetonitrile–water (20/80) at a flow rate of 2 mL/min (for details see Section 6.1). (Vertical axes are in arbitrary units.)


### 3.2. Approach B (Scheme 2)

Labeling of 2,2,2-trifluoroethyl iodide with  $^{18}\text{F}$  via  $^{18}\text{F}$ – $^{19}\text{F}$  exchange proceeded in a labeling efficiency of approx. 90–95% as reported in the literature.<sup>22</sup> After reacting 2,2,2-[ $^{18}\text{F}$ ]trifluoroethyl iodide with potassium (or sodium) glycidoxide, the intermediates were combined with 2-nitroimidazole, which resulted in three major products (Fig. 3a). By co-injection with TFMISO, these products were found more lipophilic than TFMISO (Fig. 3a). The reaction was repeated using non-radioactive 2,2,2-trifluoroethyl iodide and the final products analyzed by LC–MS. The LC–MS profile shown in Figure 3b indicates that one of the products has a mass of 378,

and the other two have the same mass of 358, suggesting the latter two products to be isomers. These mass numbers correspond to these of 1-(1,1-difluoro-2-iodoethoxy)-3-(2-nitro-1*H*-imidazol-1-yl)propan-2-ol (**7**) and (*E*) and (*Z*)-1-(1-fluoro-2-iodovinyl)-3-(2-nitro-1*H*-imidazol-1-yl)propan-2-ol (**8** and **9**), respectively. These peaks were collected and further analyzed by  $^1\text{H}$  NMR and mass spectrometry. The analysis data confirmed the final products of Approach B as Compounds **7**, **8** and **9**. This result suggests an unusual nucleophilic substitution reaction in which the oxygen nucleophile derived from glycidol attacked on the electron-deficient carbon site of the  $\text{CF}_3$ -group instead of the adjacent carbon bound to the iodine, yielding the intermediates **7**, **8** and **9**, which



**Figure 3a.** HPLC analysis of a reaction between 2,2,2-[ $^{18}\text{F}$ ]trifluoroethyl iodide and sodium glycidoxide (Approach B) co-injected with authentic TFMISO. The analytical HPLC was performed using a C18 column with a mobile phase of acetonitrile/water (20:80) at a flow rate of 2 mL/min (for details see Section 6.1). (Vertical axes are in arbitrary units.)




**Figure 3b.** LC–MS analysis of the products from Approach B. Top row: Detection of compound **7** at a mass of 378. Middle row: Detection of compounds **8** and **9** at a mass of 358. Bottom row: Detection of compounds **7**, **8** and **9** with UV absorption at 320 nm (for details see Section 6.1). (Vertical axes are in arbitrary units.)

led to the formation of Compounds **7**, **8** and **9** as the final products. **Compound 7**:  $^1\text{H}$  NMR (DMF- $d_7$ ):  $\delta$  3.83 (t, 10.4 Hz, 2H), 3.93 (dd, 5.2 Hz, 10.3 Hz, 1H), 3.98 (dd, 8.7 Hz, 13.9 Hz, 1H), 4.23 (m, 1H), 4.52 (dd, 8.5 Hz, 13.9 Hz, 1H), 4.79 (dd, 3.8 Hz, 13.8 Hz, 1H), 5.77 (d, 5.7 Hz, 1H), 7.21 (s, 1H), 7.67 (s, 1H).  $^{19}\text{F}$  NMR ( $\text{CDCl}_3$ ): 73.38 (d, 8.5 Hz); MS 378 ( $[\text{M}+\text{H}]^+$ ) and 400 ( $[\text{M}+\text{Na}]^+$ ). **Compound 8**:  $^1\text{H}$  NMR (DMF- $d_7$ ):  $\delta$  4.15 (dd, 5.3 Hz, 10.6 Hz, 1H), 4.19 (dd, 9.7 Hz, 10.6 Hz, 1H), 4.30 (m, 1H), 4.58 (dd, 8.8 Hz, 13.8 Hz, 1H), 4.84 (dd, 3.6 Hz, 13.8 Hz, 1H), 5.12 (d, 4.7 Hz, 1H), 5.83 (d, 5.7 Hz, 1H), 7.21 (s, 1H), 7.68 (s, 1H);  $^{19}\text{F}$  NMR ( $\text{CDCl}_3$ ): 74.60; MS 358 ( $[\text{M}+\text{H}]^+$ ) and 380 ( $[\text{M}+\text{Na}]^+$ ). **Compound 9**:  $^1\text{H}$  NMR (DMF- $d_7$ ):  $\delta$  4.19 (dd, 5.7 Hz, 11.4 Hz, 1H), 4.20 (dd, 9.5 Hz, 11.4 Hz, 1H), 4.23 (m, 1H), 4.53 (dd, 8.2 Hz, 13.8 Hz, 1H), 4.77 (dd, 3.8 Hz, 13.9 Hz),


5.37 (t, 4.8 Hz, 1H), 5.77 (d, 5.8 Hz, 1H), 7.20 (s, 1H), 7.67 (s, 1H);  $^{19}\text{F}$  NMR ( $\text{CDCl}_3$ ): 74.40; MS 358 ( $[\text{M}+\text{H}]^+$ ) and 380 ( $[\text{M}+\text{Na}]^+$ ). The ratio between Compounds **7**, **8** and **9** varied depending upon the base used for deprotonation of the alcohol.

### 3.3. Approach C (Scheme 3)

Heating 2,2,2-trifluoroethyl tosylate with  $^{18}\text{F}$  at 150 °C in DMF in the presence of Kryptofix 222 and  $\text{K}_2\text{CO}_3$  yielded 2,2,2- $^{18}\text{F}$ trifluoroethyl tosylate via  $^{18}\text{F}$ – $^{19}\text{F}$  exchange in a surprisingly high labeling efficiency as indicated by analytical HPLC (Fig. 4a). The 2,2,2- $^{18}\text{F}$ trifluoroethyl tosylate precursor formed in Step 1 was separated from the reaction mixture by extraction into ether.



**Figure 4a.** HPLC chromatograms of a Step 1 reaction of Approach C. The analytical HPLC was performed using a C18 column with a mobile phase of acetonitril/water (50:50) at a flow rate of 2 mL/min (for details see Section 6.1). (Vertical axes are in arbitrary units.)



**Figure 4b.** HPLC chromatograms of Step 2 and 3 reactions of Approach C. The analytical HPLC was performed using a C18 column with a mobile phase of acetonitril/water (15:85) at a flow rate of 2 mL/min (for details see Section 6.1). (Vertical axes are in arbitrary units.)



Approximately 30% ( $27 \pm 5\%$ ,  $n = 16$ ) of  $^{18}\text{F}$  was extracted into the organic layer as 2,2,2- $^{18}\text{F}$ trifluoroethyl tosylate while 40% ( $38 \pm 7\%$ ,  $n = 15$ ) remained in the aqueous layer. Step 2, in which 2,2,2- $^{18}\text{F}$ trifluoroethyl tosylate was reacted with 3-chloro-1,2-propanediol deprotonated in the presence of NaH, proceeded smoothly, and in 45–60 min, the 2,2,2- $^{18}\text{F}$ trifluoroethyl tosylate precursor was nearly completely converted into two  $^{18}\text{F}$ -labeled intermediates: one a  $^{18}\text{F}$ trifluoroethoxy compound (Peak B in Fig. 4b), which reacted with 2-nitroimidazole and gave  $^{18}\text{F}$ TFMISO in Step 3 (Fig. 4b), and the other a more hydrophilic compound (Peak A), which did not react with the imidazole. The average conversion rate from the 2,2,2- $^{18}\text{F}$ trifluoroethyl tosylate precursor into the  $^{18}\text{F}$ trifluoroethoxy intermediate (Peak B) was  $57 \pm 10\%$  ( $n = 17$ ). In Step 3, in which the  $^{18}\text{F}$ -labeled intermediates from Step 2 were reacted with 2-nitroimidazole, approximately 70% (average:  $66.5 \pm 16.1\%$ ,  $n = 16$ ) of the  $^{18}\text{F}$ trifluoroethoxy intermediate (Peak B) was incorporated into  $^{18}\text{F}$ TFMISO (Fig. 4b). This means that approximately 40% (average:  $39.6 \pm 12.3\%$ ,  $n = 16$ ) of the 2,2,2- $^{18}\text{F}$ trifluoroethyl tosylate precursor produced in Step 1 was converted into the desired final product (Figs. 4a and 4b).

The key intermediate (Peak B), which led to the formation of  $^{18}\text{F}$ TFMISO, was identified as 1,2-epoxy-3-(2,2,2- $^{18}\text{F}$ trifluoroethoxy)propane (**6**), based on the facts that (a) the  $^{18}\text{F}$ trifluoroethylation products of 3-chloro-1,2-propanediol, 3-bromo-1,2-propanediol and glycidol, appeared at the same HPLC retention time corresponding to Peak B and all afforded the same final product,  $^{18}\text{F}$ TFMISO and (b)  $^1\text{H}$  NMR spectra of the trifluoroethylation products of 3-chloro-1,2-propanediol and glycidol matched that of authentic 1,2-epoxy-3-(2,2,2-trifluoroethoxy)propane synthesized via a literature procedure (Scheme 4). Among the 3 alcohols, 3-chloro-1,2-propanediol appeared to give the key intermediate (**6**)


in a higher  $^{18}\text{F}$ -labeling efficiency than the other two. It was also noted that the stoichiometric ratio between the diol and NaH did not significantly affect the yield of the epoxide **6**: When the ratio, NaH/diol, was 1.2–1.3,  $55.7 \pm 11.5\%$  ( $n = 13$ ) of  $^{18}\text{F}$  was incorporated into the epoxide, whereas with the ratio increased to 2, the  $^{18}\text{F}$ -incorporation was  $61.5 \pm 2.9\%$  ( $n = 4$ ). This suggests that the NaH promotes both O- $^{18}\text{F}$ trifluoroethylation of the diol and cyclization, and that these two events occur in succession.

### 3.4. Approach D (Scheme 5)


The results of Approach C suggested the possibility of direct O- $^{18}\text{F}$ trifluoroethylation of the primary alcohol of 3-(2-nitroimidazolyl)-1,2-propanediol (**10**) with 2,2,2- $^{18}\text{F}$ trifluoroethyl tosylate to produce  $^{18}\text{F}$ TFMISO as shown in Scheme 5, which reduces the number of the synthesis steps to 2 and the synthesis time by approximately 1.5 h. However, our attempt to  $^{18}\text{F}$ trifluoroethylate the primary alcohol of the diol precursor in a similar fashion to Approach C was unsuccessful. It was noted that the UV absorption profile of the reaction mixture dramatically shifted after the addition of NaH suggesting loss of the nitro group of the 2-nitroimidazole ring, which has its major absorption at 320 nm. Proton NMR data strongly suggested that NaH prompted intramolecular nucleophilic substitution of the nitro group yielding the cyclized product **11**. This indicates that the nucleophile derived from the secondary alcohol of the propanediol moiety intramolecularly attacks on the carbon at the 2 position of the imidazole ring and triggers the departure of the nitro group, which results in the five-membered cyclic ether formation. The five-membered cyclic ether **11** shows distinct  $^1\text{H}$  NMR spectra from those of the six-membered one **12** including the signal at 5.3 ppm from the proton attached to the chiral carbon; in comparison, the chemical shift of the proton at the chiral carbon of Compound **12** is 3.9 ppm<sup>23</sup> (both in  $\text{CD}_3\text{OD}$ ).  $^1\text{H}$  NMR of the product: ( $\text{DMF-d}_7$ )  $\delta$  3.78 (dd, 4.30 Hz, 12.4 Hz, 1H), 3.89 (dd 3.70 Hz, 12.4 Hz, 1H), 4.08 (t, 8.1 Hz, 1H), 4.27 (t, 9.1 Hz, 1H), 5.34 (m, 1H) 6.53 (2, 1H), 6.70 (d, 1.3 Hz); ( $\text{CD}_3\text{OD}$ )  $\delta$  3.74 (dd, 4.25 Hz, 12.7 Hz, 1H), 3.90 (dd 3.30 Hz, 12.7 Hz, 1H), 4.04 (dd, 7.1 Hz, 9.3 Hz, 1H), 4.22 (t, 9.2 Hz, 1H), 5.32 (m, 1H) 6.53 (d, 1.3 Hz, 1H), 6.70 (d, 1.3 Hz); MS: 163 ( $[\text{M}+\text{Na}]^+$ ).

### 4. Discussion

We commenced this TFMISO radiolabeling project by examining a simple halogen- $^{18}\text{F}$  exchange method in which a 2-halo-2,2-difluoroethoxy ( $\text{XCF}_2\text{CH}_2\text{O}-$ ,  $\text{X} = \text{Cl}/\text{Br}$ ) analog of TFMISO (**3**) is used as the precursor, and the halogen (X) is replaced with  $^{18}\text{F}$ -fluoride in a nucleophilic substitution reaction (Approach A, Scheme 1). Considering the relatively short half-life of  $^{18}\text{F}$ , 110 min, it is essential that the entire radiosynthesis be complete within a period of 1–2 half-lives of the radionuclide in order to obtain a sufficient amount of the final product for in vivo imaging. We expected reasonably good  $^{18}\text{F}$  incorporation into TFMISO molecules after heating the  $\text{ClCF}_2$ -precursor (**4**) with  $\text{K}^{18}\text{F}$  at 100–150 °C for 10–30 min. Our expectation was based on a relatively large volume of literature describing the use of halogen- $^{18}\text{F}$  ex-



Scheme 4.



Scheme 5.

change for  $^{18}\text{F}$ -labeling of a variety of compounds<sup>24</sup> including a few trifluoromethylated aromatic compounds such as  $\alpha,\alpha,\alpha$ -trifluorotoluene or trifluoromethyl-benzophenone which were labeled from their corresponding halo-difluoromethyl analog precursors.<sup>24d,e</sup> However, contrary to our expectation, we found that the predominant mechanism governing the reaction between our OH-protected  $\text{XCF}_2$ -precursor (**4**) and  $^{18}\text{F}$ fluoride was elimination of the halogen rather than halogen- $^{18}\text{F}$  substitution, resulting in only a trace amount of  $^{18}\text{F}$ TFMISO and a large amount of the unlabeled elimination product (**5**) (Fig. 2b).

After our attempt of this simple one-pot method revealed unexpected outcomes, we switched our strategy to O- $^{18}\text{F}$ trifluoroethylation approaches using 2,2,2- $^{18}\text{F}$ trifluoroethyl halide or tosylate as a  $^{18}\text{F}$ trifluoroethylating agent: Approaches B and C depicted in Schemes 2 and 3, respectively. Approach B was designed assuming that in parallel to the nucleophilic reactions between alkylhalides and glycidol which give glycidyl ethers,<sup>25</sup> a similar reaction between 2,2,2- $^{18}\text{F}$ trifluoroethyl iodide and glycidol would lead to the intermediate, 1,2-epoxy-3-(2,2,2- $^{18}\text{F}$ trifluoroethoxy)propane (**6**), which, condensed with 2-nitroimidazole, would produce  $^{18}\text{F}$ TFMISO. 2,2,2- $^{18}\text{F}$ Trifluoroethyl iodide can be prepared via  $^{18}\text{F}$ - $^{19}\text{F}$  exchange in high radiochemical yield as reported in the literature.<sup>22</sup> However, contrary to our expectation, the oxygen nucleophile derived from glycidol did not replace the iodine of the trifluoroethyl iodide molecule. Instead, the nucleophile attacked on the carbon of the  $\text{CF}_3$  group resulting in 1,1-difluoro-2-iodoethoxy and 1-fluoro-2-iodovinylxy analogs of TFMISO (Scheme 2, Figs. 3a and 3b). In stark contrast,  $^{18}\text{F}$ trifluoroethyl tosylate yielded the key intermediate (**6**) smoothly without complication, and, through this intermediate, the 2,2,2- $^{18}\text{F}$ trifluoroethyl group was successfully incorporated into the TFMISO molecule giving  $^{18}\text{F}$ TFMISO (**2**) as the final product (Scheme 3, Fig. 4b). 2,2,2- $^{18}\text{F}$ Trifluoroethyl tosylate was prepared via  $^{18}\text{F}$ - $^{19}\text{F}$  exchange in good radiochemical yield (Fig. 4a), which was also contrary to our expectation that the overwhelmingly predominant mechanism underlying the reaction between the tosylate and  $^{18}\text{F}$ fluoride would be nucleophilic  $^{18}\text{F}$ -tosyl substitution such that radiolabeling of 2,2,2-trifluoroethyl tosylate via  $^{18}\text{F}$ - $^{19}\text{F}$  exchange would be unlikely to occur.

The unusual chemistry observed in Approaches A–C was derived from remarkable electron-withdrawing effects of the fluorine atom. Base-promoted dehydrochlorination of 2-chloro-2,2-difluoro-1-phenylethane ( $\text{ClF}_2\text{CCH}_2\text{C}_6\text{H}_5$ ) with sodium ethoxide occurs 50 times quicker than that of 2-chloro-1-phenylethane ( $\text{ClCH}_2\text{CH}_2\text{C}_6\text{H}_5$ ),<sup>26,27</sup> and the difference in the rate of dehydrobromination between 1,2-dibromo-2,2-difluoro-1-phenylethane ( $\text{BrF}_2\text{CC}-\text{HBrC}_6\text{H}_5$ ) and 1,2-dibromo-1-phenylethane ( $\text{BrCH}_2\text{CHBrC}_6\text{H}_5$ ) is 250 times,<sup>28</sup> which suggest that the 2 electron-withdrawing fluorine atoms of the  $\text{XCF}_2$  ( $\text{X} = \text{Cl}/\text{Br}$ ) group greatly facilitate the departure of the halogen leaving group. Compared to these accelerated halogen elimination reactions, substitution of the halogen ( $\text{X}$ ) of the  $\text{XCF}_2$  moiety with a nucleophile such as fluoride or alkoxide appears much slower.<sup>27,29</sup> Thus, it is most likely that in our reaction system, the halogen elimination promoted by the basic environment created by the Kryptofix- $\text{K}_2\text{CO}_3$  complex occurred overwhelmingly rapidly compared to the  $\text{Cl}$ -(or  $\text{Br}$ -) $^{18}\text{F}$  exchange reaction. As a consequence, only a trace amount of  $^{18}\text{F}$ TFMISO was produced while most of the  $\text{ClCF}_2$ -precursor was converted into the 2,2-difluorovinylxy-analog of TFMISO (**5**). Although iodide is a better leaving group, use of the  $\text{ICF}_2$ -precursor as an alternative might not be helpful because the rate of I-elimination could be several orders of magnitude larger than that of Cl-elimination<sup>27</sup> and would likely dominate the  $^{18}\text{F}$ -I substitution reaction.

The electronegativity of fluorine also affects greatly the reactivity of the halogen leaving group on the carbon adjacent to a fluoromethyl group. The reactivity of the iodide leaving group of

2-fluoroethyl iodide toward a nucleophile such as sodium thiophenoxide dropped exponentially with increasing number of fluorine atoms attached to the position 2-carbon.<sup>30</sup> Bodor and Huang<sup>31</sup> reported that because of the high electronegativity of fluorine, replacement of one of the three hydrogen atoms of the  $\text{CH}_3$  group of ethyl iodide with a fluorine atom changes the charge on the methyl carbon center from negative to positive, and with additional two fluorine atoms replacing the remaining two hydrogen atoms, which converts the  $\text{CFH}_2$  moiety into a  $\text{CF}_3$  group, the same carbon center becomes 24 times more positive, while the charge on the  $\text{CH}_2\text{I}$  carbon remains negative. Because of deactivation of the halide leaving group in trifluoroethyl halide by the three electron-withdrawing fluorine atoms of the  $\text{CF}_3$  group, Satter et al. observed that a nucleophile such as  $^{18}\text{F}$ fluoride replaces one of the three fluorine atoms instead of the halogen ( $\text{Cl}$ ,  $\text{Br}$  or  $\text{I}$ ) resulting in 2,2,2- $^{18}\text{F}$ trifluoroethyl halide instead of 1,1,1,2- $^{18}\text{F}$ tetrafluoroethane in remarkably high radiochemical yields,<sup>22</sup> which we also confirmed in Approach B. Presumably by a similar mechanism,<sup>31</sup> 2,2,2- $^{18}\text{F}$ trifluoroethyl tosylate was produced via  $^{18}\text{F}$ - $^{19}\text{F}$  exchange (Approach C, Scheme 3) in a surprisingly high labeling efficiency. Aigbirhio et al.<sup>32</sup> produced 1,1,1,2- $^{18}\text{F}$ tetrafluoroethane from 2,2,2-trifluoroethyl tosylate via nucleophilic substitution with  $^{18}\text{F}$  using a mildly pressurized reaction vessel in a radiochemical yield of 50% but also reported that due to the  $^{18}\text{F}$ - $^{19}\text{F}$  exchange reaction simultaneously occurring and competing with the tosyl- $^{18}\text{F}$  substitution reaction, the specific activity of the substitution product 1,1,1,2- $^{18}\text{F}$ tetrafluoroethane was 2–3 orders of magnitude lower than expected. Thus, two competing mechanisms, that is, fluorine–fluorine exchange, which produces 2,2,2- $^{18}\text{F}$ trifluoroethyl tosylate, and nucleophilic substitution of the tosyl leaving group, which produces 1,1,1,2- $^{18}\text{F}$ tetrafluoroethane, appear to underlie the reaction between the nucleophile fluoride and 2,2,2-trifluoroethyl tosylate.

There were striking differences between 2,2,2- $^{18}\text{F}$ trifluoroethyl tosylate and iodide as a  $^{18}\text{F}$ trifluoroethylating agent.  $^{18}\text{F}$ Trifluoroethylation of an alcohol, such as 3-chloro-1,2-propanediol, 3-bromo-1,2-propanediol or glycidol, with 2,2,2- $^{18}\text{F}$ trifluoroethyl tosylate proceeds smoothly affording a  $^{18}\text{F}$ trifluoroethylether such as the key intermediate for the  $^{18}\text{F}$ TFMISO production: 1,2-epoxy-3-(2,2,2- $^{18}\text{F}$ trifluoroethoxy)propane (**6**) (Schemes 3 and 4). By contrast, our attempt of O- $^{18}\text{F}$ trifluoroethylation of the same alcohol using 2,2,2- $^{18}\text{F}$ trifluoroethyl iodide failed since unusual substitution reactions occurred in which the iodide leaving group was not replaced with the same oxygen nucleophile. Instead one or two of the 3 fluorine atoms of the  $\text{CF}_3$ -group were replaced, resulting in the formation of 1-iodo-2,2- $^{18}\text{F}$ difluoroethyl and 1-iodo-2- $^{18}\text{F}$ fluoro-vinyl ethers. As a consequence, the reaction between 2,2,2- $^{18}\text{F}$ trifluoroethyl iodide and glycidoxide led to the production of 1-iodo-2,2- $^{18}\text{F}$ difluoroethoxy and 1-iodo-2- $^{18}\text{F}$ fluoro-vinylxy analogs of  $^{18}\text{F}$ TFMISO (Scheme 2). Obviously, the same oxygen nucleophile which reacts on the carbon attached to the tosyl group of 2,2,2-trifluoroethyl tosylate and replaced the tosyl leaving group attacks on the  $\text{CF}_3$  site of 2,2,2-trifluoroethyl iodide, replacing one or two of the fluorine atoms instead of the iodide leaving group. Similar complications have been observed in nucleophilic substitution reactions with 2,2,2-trifluoroethyl halides.<sup>33</sup> The differences observed in this investigation between trifluoroethyl halide and tosylate as a trifluoroethylating agent are in part similar to the differences between alkyl tosylates and halides. Alkyl tosylates are considered to be ‘harder’ electrophiles than the counterpart halides, which makes tosylates more reactive in nucleophilic substitution reactions and less reactive in accompanying and competing side reactions. Depuy et al. observed that the  $\text{S}_{\text{N}}2$  reactivity of phenylethyl tosylate toward sodium ethoxide is four times higher than that of the counterpart iodide whereas the accompa-

nying elimination reaction was 68 times slower with the tosylate than with the iodide, as a result of which the yield of the nucleophilic substitution product, phenylethyl ether, was approximately 20–30 times higher with the tosylate than the iodide.<sup>26,34</sup> Similar differences in  $S_N2$  and E2 reactivity between ethyltosylate and ethylbromide have also been reported.<sup>35</sup> In the case of *O*-[ $^{18}\text{F}$ ]trifluoroethylation reported here, the differences between [ $^{18}\text{F}$ ]trifluoroethyl tosylate and iodide as an electrophile appeared to be more pronounced. Besides the general differences as electrophiles between tosylates and halides, the most striking difference which makes [ $^{18}\text{F}$ ]trifluoroethyl tosylate a superior [ $^{18}\text{F}$ ]trifluoroethylating agent is that the two different nucleophiles, [ $^{18}\text{F}$ ]fluoride and an alkoxide such as glycidoxide, react on the two different carbon sites of the trifluoroethyl moiety of the tosylate, that is, [ $^{18}\text{F}$ ]fluoride on C-2 and glycidoxide on C-1, whereas, in contrast, these nucleophiles both attack on the same carbon of trifluoroethyl iodide (Scheme 6). Further empirical and theoretical investigations are needed to elucidate the mechanisms by which trifluoroethyl halide and trifluoroethyl tosylate react with a nucleophile differently.

After [ $^{18}\text{F}$ ]TFMISO (**2**) was successfully produced via the three-step procedure (Scheme 3), we attempted direct *O*-[ $^{18}\text{F}$ ]trifluoroethylation of the primary alcohol of 3-(2-nitroimidazolyl)-1,2-propanediol (**10**) (Scheme 5) using the same [ $^{18}\text{F}$ ]trifluoroethylating agent to produce [ $^{18}\text{F}$ ]TFMISO. However, this approach was unsuccessful because of intramolecular nucleophilic substitution of the nitro group of the nitroimidazole moiety, which gave a five-membered cyclic ether (**11**). It was unexpected that the nucleophile derived from the secondary alcohol, instead of the primary alcohol, of the propanediol moiety attacks intramolecularly on the carbon at the 2 position of the imidazole ring and triggers the departure of the nitro group, resulting in the five-membered cyclic ether formation. The formation of the six-membered cyclic ether (**12**) has been reported to occur when the cyclization is prompted by removal of the primary OH-protection of the derivative of Compound **9** in which primary and secondary hydroxyl groups are both protected.<sup>23</sup> Similar to our finding depicted in Scheme 5, Fekner et al. observed that, in a reaction of 3-(2-(2-nitrophenyl)-benzimidazolyl)-propane-1,2-diol with NaH, a cyclic ether was formed from intramolecular nucleophilic substitution of the nitro group with the secondary alkoxide of the propanediol moiety while no cyclization occurred with the primary alkoxide.<sup>36</sup> They suggested that the cyclization with the secondary alkoxide is kinetically more favored. This result of our attempt to directly [ $^{18}\text{F}$ ]trifluoroethylate 3-(2-nitroimidazolyl)-1,2-propanediol (**10**) suggests that it is essential to avoid the intramolecular nucleophilic substitution of the nitro group by choosing a base which deprotonates the primary alcohol but prevent the alkoxide from eliminating the nitro group.

As proven here, the use of 2,2,2-[ $^{18}\text{F}$ ]trifluoroethyl tosylate as a [ $^{18}\text{F}$ ]trifluoroethylating agent is a highly efficient way to label a compound containing a trifluoroethyl group with  $^{18}\text{F}$ . However, there is a limitation of this method, which is the low specific activity of the final product. The average specific activity of [ $^{18}\text{F}$ ]TFMISO produced via Approach C was  $80 \pm 7 \mu\text{Ci}/\mu\text{mol}$  at EOS ( $n = 12$ ) and is anticipated to increase to approximately  $0.2 \text{ mCi}/\mu\text{mol}$  if the above-mentioned approach (Approach D), where the diol precursor (**10**) is directly *O*-[ $^{18}\text{F}$ ]trifluoroethylated with 2,2,2-[ $^{18}\text{F}$ ]trifluoroethyl tosylate, is improved and successfully implemented. Low

specific activity does not seem to be an issue when the [ $^{18}\text{F}$ ]trifluoroethylated final product is used as a hypoxia marker as is the case for [ $^{18}\text{F}$ ]TFMISO. As Wyss et al. have demonstrated using nanoPET, the amount of unlabeled FMISO contained in a [ $^{18}\text{F}$ ]FMISO injection does not influence quality of the tumor hypoxia image up to 300 mg/kg.<sup>37</sup> Likewise, for in vivo MR imaging of hypoxia with TFMISO, a dose greater than or equal to 75 mg/kg was used.<sup>18</sup> However, when high specific activity is required, this  $^{18}\text{F}$ – $^{19}\text{F}$  exchange-based method is disadvantageous compared to a no-carrier-added approach such as the one we tried in Approach A (Scheme 1) if (a) elimination of the leaving group does not overwhelm its substitution with  $^{18}\text{F}$  and (b) no isotopic dilution occurs. It may be noteworthy that in labeling of a trifluoroalkyl group in a complex molecule with  $^{18}\text{F}$ , which often involves unusual chemistry as reported here, even a no-carrier-added approach does not necessarily result in a high specific activity radiotracer.<sup>20</sup>

[ $^{18}\text{F}$ ]TFMISO resulting from Approach C is a racemate of the two enantiomers. By using the *S* or *R* form of 3-chloro-1,2-propanediol or glycidol in Step 2, [ $^{18}\text{F}$ ]TFMISO of high enantiopurity can be synthesized. However, although enantiomeric isomers of a drug often exhibit distinct biological behavior and potency, it is unlikely that one enantiomer of [ $^{18}\text{F}$ ]TFMISO shows better properties as a hypoxia marker than the other or the racemate: this issue has been investigated in the past using TFMISO analog hypoxia markers such as FMISO or pimonidazole,<sup>38,39</sup> and no differences were found between an enantiopure isomer and the racemic mixture in pharmacokinetics, biodistribution, toxicity or metabolism of the hypoxia marker.


## 5. Conclusions

This investigation has identified 2,2,2-[ $^{18}\text{F}$ ]trifluoroethyl tosylate as an excellent [ $^{18}\text{F}$ ]trifluoroethylating agent, which can convert an alcohol into the corresponding [ $^{18}\text{F}$ ]trifluoroethyl ether in a high efficiency. 2,2,2-[ $^{18}\text{F}$ ]Trifluoroethyl tosylate can be produced via  $^{18}\text{F}$ – $^{19}\text{F}$  exchange in good radiochemical yield. Unlike [ $^{18}\text{F}$ ]trifluoroethylation with 2,2,2-[ $^{18}\text{F}$ ]trifluoroethyl halide, which promotes unusual nucleophilic substitution reactions, [ $^{18}\text{F}$ ]trifluoroethylation with 2,2,2-[ $^{18}\text{F}$ ]trifluoroethyl tosylate proceeds smoothly without complication. Using 2,2,2-[ $^{18}\text{F}$ ]trifluoroethyl tosylate as the [ $^{18}\text{F}$ ]trifluoroethylating agent, the bimodal hypoxia marker TFMISO (**1**) was successfully labeled with  $^{18}\text{F}$  (**2**). In addition to *O*-[ $^{18}\text{F}$ ]trifluoroethylation, an amine or a thiol can also be [ $^{18}\text{F}$ ]trifluoroethylated with the same [ $^{18}\text{F}$ ]trifluoroethylating agent. Thus the [ $^{18}\text{F}$ ]trifluoroethylation method using [ $^{18}\text{F}$ ]trifluoroethyl tosylate as described here is a novel and versatile tool for  $^{18}\text{F}$ -radiolabeling of a wide variety of pharmaceuticals containing a *O*-, *N*- or *S*-trifluoroethyl group in their molecules.

## 6. Experimental

### 6.1. General methods

TFMISO was purchased from SynChem OHG Laboratories (Altenburg, Germany). Reagents were used as received from commercial sources. Flash chromatography was carried out using silica gel 170–400 mesh (Fisher, Pittsburgh, PA). Proton ( $^1\text{H}$ ) and fluorine ( $^{19}\text{F}$ ) NMR spectra were recorded at 500 MHz using a Bruker DRX spectrometer. Mass spectra were obtained with a PE SCIEX API100 mass spectrometer. Radiochemical reactions were carried out in sealed 5 mL Reacti-vials (Pierce, Rockford, IL). Analytical HPLC was performed using a C18 Nova-Pak column (4  $\mu\text{m}$ ,  $4.6 \times 150 \text{ mm}$ ) (Waters, Milford, MA) with a mobile phase of acetonitrile and water at a flow rate of 2 mL/min. Semi-preparative HPLC was performed using a C18 Nova-Pak column (6  $\mu\text{m}$ ,



Scheme 6.



7.8 × 300 mm) with a mobile phase of acetonitrile–water (15/85) at a flow rate of 5 mL/min. The HPLC output was monitored using a Diode Array Detector (SPD-M10AVP) (Shimadzu, Columbia, MD) and a radiation detector (Bioscan Flow-Count, Washington DC).

## 6.2. Preparation of the OH-protected ClCF<sub>2</sub>-precursor (**4**, Scheme 1)

The ClCF<sub>2</sub>-precursor (**3**) for Approach A was synthesized by reacting 2-epoxy-3-(2-chloro-2,2-difluoroethoxy)propane with 2-nitroimidazole according to the literature procedure.<sup>6</sup> 2-Epoxy-3-(2-chloro-2,2-difluoroethoxy)propane was prepared following the procedure reported by Brey and Torrant<sup>40</sup> with modifications. Briefly 3.6 mL of 10% sodium hydroxide solution was added to a mixture of 1.0 g of 2-chloro-2,2-difluoroethanol (Matrix, Columbia, SC) and 0.78 g of epichlorohydrin (Fluka, Buchs, Switzerland) and the mixture stirred at room temperature overnight. The organic layer was separated and used without further purification. <sup>1</sup>H NMR (CDCl<sub>3</sub>); δ 2.65 (dd 2.7 Hz, 4.7 Hz, 1H), 2.83 (dd 4.70 Hz, 4.75 Hz, 1H), 3.19 (m, 1H), 3.58 (dd 5.85 Hz, 11.8 Hz, 1H), 3.95–4.07 (m, 3H). 2-Epoxy-3-(2-chloro-2,2-difluoroethoxy)propane (740 mg) prepared as above was reacted with 243 mg of 2-nitroimidazole (Aldrich, St. Louis, MO) in ethanol (20 mL) at 110 °C for 2.5 h in the presence of 68 mg of K<sub>2</sub>CO<sub>3</sub>. After evaporation of ethanol, the product 3-(2-nitroimidazolyl)-1-(2-chloro-2,2-difluoroethoxy)-propane-2-ol (**3**), was isolated by silica gel column chromatography using a solvent of ethylacetate/hexane (3:1). <sup>1</sup>H NMR: (CD<sub>3</sub>OD) δ 3.59 (dd 5.2 Hz, 10.9 Hz, 1H), 3.64 (dd, 5.1 Hz, 10.5 Hz, 1H), 4.00 (dt, 1.8 Hz, 11.4 Hz, 2H), 4.00 (m, 1H), 4.32 (dd, 8.4 Hz, 13.9 Hz, 1H), 4.64 (dd, 3.6 Hz, 13.9 Hz), 7.03 (d, 0.95 Hz, 1H), 7.34 (d, 0.90 Hz, 1H); <sup>19</sup>F NMR (CDCl<sub>3</sub>): δ 63.04; MS (ESI): 286 ([M+H]<sup>+</sup>), 308 ([M+Na]<sup>+</sup>), 320 ([M+Cl]<sup>−</sup>). The hydroxyl group of the ClCF<sub>2</sub>-precursor (**3**) was tetrahydropyranylated in THF (20 mL) using 2,3-dihydro-4H-pyran (2 mL) (Aldrich) and pyridinium *p*-toluenesulfonate (0.6 g) (Aldrich) as reported by Miyashita et al.<sup>41</sup> The reaction mixture was heated at 80 °C for 3.5 h and the progress of the reaction was monitored by analytical HPLC with a mobile phase of acetonitrile–water (40/60) as the double peak corresponding to the two diastereoisomers of the OH-protected product grew. The OH-protected ClCF<sub>2</sub>-precursor (**4**) was separated by silica gel column chromatography using a solvent of ethylacetate/hexane (1:1). Yield 43%; <sup>1</sup>H NMR (CDCl<sub>3</sub>), (mixture of diastereoisomers): δ 1.44–1.68 (m, 12H), 3.20–3.24 (m, 1H), 3.29–3.34 (m, 1H), 3.43–3.47 (m, 1H), 3.71–3.74 (m, 2H), 3.77 (dd, 4.6 Hz, 10.6 Hz, 1H), 3.81–3.83 (m, 1H), 3.86 (dd, 3.7 Hz, 10.3 Hz, 1H), 3.91–4.06 (m, 4H), 4.07–4.10 (m, 1H), 4.24 (sextet, 4.2 Hz, 1H), 4.29–4.31 (m, 1H), 4.44 (dd, 7.5 Hz, 14.1 Hz, 1H) 4.54 (dd, 8.1 Hz, 14.0 Hz, 1H), 4.66 (m, 1H), 4.77 (dd, 3.8 Hz, 14.1 Hz, 1H), 4.87 (dd, 3.8 Hz, 14.1 Hz, 1H), 7.13 (d, 0.8 Hz, 1H), 7.14 (s, 2H), 7.20 (d, 0.65 Hz, 1H); <sup>19</sup>F NMR (CDCl<sub>3</sub>): δ 61.41, 61.49; MS (ESI): 370 ([M+H]<sup>+</sup>), 392 ([M+Na]<sup>+</sup>).

## 6.3. Preparation of 3-(2-nitroimidazolyl)-1,2-propanediol (**10**, Scheme 5)

The diol precursor for Approach D (**10**) was synthesized following the method of Beaman et al.<sup>6</sup> Briefly, 400 mg of 2-nitroimidazole and 530 mg of glycidol (Acros, Geel, Belgium) were reacted in 30 mL of ethanol in the presence of 40 mg of K<sub>2</sub>CO<sub>3</sub>. When the exothermic reaction started, the heater was shut off, but stirring continued for 40 min. After unreacted glycidol and the solvent were evaporated under vacuum, the final product (**10**) was separated by silica gel column chromatography using a solvent of ethylacetate/methanol (3:1). Yield 45%; <sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 3.54 (dd, 5.5 Hz, 11.35 Hz, 1H), 3.57 (dd, 5.5 Hz, 11.35 Hz, 1H), 3.94 (m, 1H), 4.36 (dd, 8.6 Hz, 13.9 Hz), 4.74 (dd,

3.4 Hz, 13.9 Hz), 7.12 (s, 1H), 7.44 (s, 1H); MS (ESI): 210 ([M+Na]<sup>+</sup>), 397 ([2 M+Na]<sup>+</sup>).

## 6.4. Preparation of Kryptofix-K<sup>18</sup>F complex

[<sup>18</sup>F]Fluoride was produced via the <sup>18</sup>O(p,n)<sup>18</sup>F nuclear reaction using a biomedical cyclotron TR19/9 (EBCO Technologies, British Columbia, Canada). Fifty to 90 mCi of [<sup>18</sup>F]fluoride in 100–200 μL of H<sub>2</sub><sup>18</sup>O was added to a Reacti-vial containing acetonitrile (300 μL), water (50–100 μL), Kryptofix 222 (10–13 mg) and K<sub>2</sub>CO<sub>3</sub> (2–3 mg). The solvents were evaporated azeotropically by repeatedly adding 500 μL acetonitrile until dry Kryptofix-K<sup>18</sup>F complex was obtained.

## 6.5. Radiolabeling of TFMISO with <sup>18</sup>F via Cl-<sup>18</sup>F substitution (Approach A, Scheme 1)

To the dried Kryptofix-K<sup>18</sup>F complex prepared as above, 6–8 mg of the OH-protected ClCF<sub>2</sub>-precursor (**4**) dissolved in DMF (200 μL) was added, and the reaction mixture heated at 80–150 °C for 10 min. And then the OH-protection was removed with 200 μL of 0.1 N HCl at 80 °C. The progress of the reaction was monitored by injecting an aliquot of the reaction mixture into analytical HPLC running with a mobile phase of acetonitrile–water (40/60) before hydrolysis or 20/80 after hydrolysis). After hydrolysis, the formation of [<sup>18</sup>F]TFMISO was examined by co-injecting the reaction mixture with authentic TFMISO. The most prominent unlabeled by-product was isolated by semi-preparative HPLC and characterized by mass spectrometry and <sup>1</sup>H/<sup>19</sup>F NMR.

## 6.6. <sup>18</sup>F-labeling of TFMISO via O-[<sup>18</sup>F]trifluoroethylation with 2,2,2-[<sup>18</sup>F]trifluoroethyl iodide (Approach B, Scheme 2)

To the dried Kryptofix-K<sup>18</sup>F complex prepared as above, 5–10 μL of 2,2,2-trifluoroethyl iodide (Aldrich) in DMF (200 μL) was added, and the reaction mixture heated at 130 °C for 5 min. Incorporation of <sup>18</sup>F into CF<sub>3</sub>CH<sub>2</sub>I was monitored by injecting an aliquot of the reaction mixture into analytical HPLC running with a mobile phase of acetonitrile–water (40/60). [<sup>18</sup>F]CF<sub>3</sub>CH<sub>2</sub>I was distilled into a second vial containing 8 mg of glycidol and 10 mg of powdered KOH (or 6 mg of NaH) in 200 μL of anhydrous DMF, and the reaction stirred at 80 °C (KOH) or room temperature (NaH) for 30 min. This reaction mixture was transferred into a third vial containing 12–13 mg of 2-nitroimidazole and 1–2 mg of K<sub>2</sub>CO<sub>3</sub> in 200 μL of ethanol and heated at 100 °C for 30 min. The progress of the reaction was monitored by analytical HPLC using a mobile phase of acetonitrile–water (20/80). In order to characterize the final products, similar reactions were carried out starting with non-radioactive CF<sub>3</sub>CH<sub>2</sub>I and the final products isolated using LC–MS equipped with a C18 preparative column (XBridge, Waters), a photodiode array detector (Model 2998, Waters) and a mass detector (Model 3100, Waters) with a mobile phase of acetonitrile–water (30/70) containing 0.1% of trifluoroacetic acid. The purified products were analyzed by <sup>1</sup>H/<sup>19</sup>F NMR and mass spectrometry.

## 6.7. <sup>18</sup>F-labeling of TFMISO via O-[<sup>18</sup>F]trifluoroethylation with 2,2,2-[<sup>18</sup>F]trifluoroethyl tosylate (Approach C, Scheme 3)

*Step 1: Preparation of 2,2,2-[<sup>18</sup>F]trifluoroethyl tosylate:* To the dried Kryptofix-K<sup>18</sup>F complex prepared as above, 10–20 mg of 2,2,2-trifluoroethyl *p*-toluenesulfonate (Fluka) in DMF (200 μL) was added, and the reaction mixture heated at 150 °C for 10 min. Incorporation of <sup>18</sup>F into the tosylate precursor was monitored by analytical HPLC using a mobile phase of acetonitrile–water (50/50). From the reaction mixture, 2,2,2-[<sup>18</sup>F]trifluoroethyl tosylate was extracted into ether (1 mL) and the organic layer washed with

brine (0.1 mL) followed by water (0.1 mL), and dried over sodium sulfate. After evaporation of ether, 2,2,2-[<sup>18</sup>F]trifluoroethyl tosylate was dissolved in anhydrous DMF.

**Step 2: O-[<sup>18</sup>F]Trifluoroethylation of 3-chloro-1,2-propanediol:** To a Reacti-vial containing 2–8 mg of NaH (60% in mineral oil) suspended in 100 µL of dry DMF, 4–15 mg of 3-chloro-1,2-propanediol in anhydrous DMF was added at 0 °C followed by the [<sup>18</sup>F]trifluoroethyl tosylate solution obtained from Step 1, and stirred at room temperature for 45–60 min. An aliquot of the reaction mixture was analyzed by analytical HPLC running with a mobile phase of acetonitrile–water (15/85).

**Step 3: Reaction of the intermediate products from Step 2 with 2-nitroimidazole:** To a Reacti-vial containing 10–13 mg of 2-nitroimidazole in 100 µL of DMF, an equivalent amount of sodium methoxide in methanol was added and heated at 150 °C for 3 min, the reaction mixture let cool to 120 °C, and then the Step 2 reaction mixture added through a 0.45 µm membrane filter (Supelco, PA). The vial was heated at 120 °C for 30 min. This procedure was adopted from Beaman et al.<sup>6</sup> and used with modifications. Alternatively, the reaction mixture of Step 2 was added to a vial containing 2-nitroimidazole and K<sub>2</sub>CO<sub>3</sub> in 0.3 mL of ethanol and the vial heated at 100 °C for 30 min. The progress of the reaction was monitored by analytical HPLC running with a mobile phase of acetonitrile–water (15/85). The <sup>18</sup>F-labeled product which eluted at the retention time corresponding to that of authentic TFMISO was isolated by semi-preparative HPLC, concentrated by solid phase extraction using a tC18 SepPak Plus cartridge (Waters) and eluted with 2 mL of methanol and the solvent evaporated. The final product was confirmed as [<sup>18</sup>F]TFMISO by HPLC and mass spectrometry. MS (ESI): 292 ([M+Na]<sup>+</sup>), 304 ([M+Cl]<sup>−</sup>). The radiochemical and chemical purity of the purified final product were determined by analytical HPLC and found to be 100% and greater than 98%, respectively. The specific activity of [<sup>18</sup>F]TFMISO was determined by dividing the radioactivity of the radiotracer by its mass, which was calculated by comparing the area under its HPLC UV peak at 320 nm with that of a standard TFMISO solution of known concentration.

#### 6.8. Identification of the [<sup>18</sup>F]trifluoroethoxy intermediate produced in Step 2 of Approach C as Compound 6 (Fig. 4b, Schemes 3 and 4)

The [<sup>18</sup>F]trifluoroethoxy intermediate produced in Step 2 of Approach C (Peak B in Fig. 4b), which led to [<sup>18</sup>F]TFMISO formation in Step 3 (Fig. 4b and Scheme 3) was identified as follows. In addition to 3-chloro-1,2-propanediol, two other alcohols, 3-bromo-1,2-propanediol and glycidol, were treated with NaH and reacted with 2,2,2-[<sup>18</sup>F]trifluoroethyl tosylate in a similar fashion to 3-chloro-1,2-propanediol and the products analyzed by analytical HPLC. These <sup>18</sup>F-labeled intermediates were further reacted with 2-nitroimidazole in a similar fashion to the procedure with 3-chloro-1,2-propanediol, and the reactions monitored by analytical HPLC. The formation of the epoxide intermediate (**6**) was confirmed by repeating the O-trifluoroethylation reactions using non-radioactive 2,2,2-trifluoroethyl tosylate and the two alcohol, 3-chloro-1,2-propanediol and glycidol (Routes 1 and 2, Scheme 4) and comparing the <sup>1</sup>H NMR spectra of the trifluoroethoxy products with that of the reference compound 1,2-epoxy-3-(2,2,2-trifluoroethoxy)propane. The reference compound was synthesized from 2,2,2-trifluoroethanol and epichlorohydrin following the method of Brey and Torrant.<sup>40</sup> (Route 3, Scheme 4). <sup>1</sup>H NMR (DMF-d<sub>7</sub>) δ 2.63 (dd, 2.8 Hz, 5.2 Hz, 1H), 2.80 (t, 4.4 Hz, 1H), 3.20 (m, 1H), 3.52 (dd, 6.6 Hz, 11.7 Hz, 1H), 4.01 (dd, 2.5 Hz, 11.8 Hz, 1H), 4.17 (q, 9.3 Hz, 2H). The reactions between 3-chloro-1,2-propanediol (20 mg, 0.18 mmole) and non-radioactive 2,2,2-trifluoroethyl tosylate (22 mg, 0.09 mmole) (Route 1) and between glycidol (15 mg,

0.19 mmole) and the non-radioactive tosylate (24 mg, 0.09 mmole) (Route 2) were carried out in DMF-d<sub>7</sub> in the presence of NaH (60%, washed with pentane and dried under a stream of Ar) in a similar fashion as described above (Approach C).

#### 6.9. <sup>18</sup>F-labeling of TFMISO using 3-(2-nitroimidazolyl)-1,2-propanediol (**10**) as the precursor (Approach D, Scheme 5)

[<sup>18</sup>F]Trifluoroethyl tosylate produced as described above was added to a DMF solution containing 8 mg of the diol precursor (**10**) and 3 mg of 60% NaH and the reaction mixture stirred at room temperature for 45 min. The progress of the reaction was examined by analytical HPLC with a mobile phase of acetonitrile–water (15/85). The deprotonation reaction of the diol precursor (**10**) with NaH was further examined by NMR as follows. To a Reacti-vial containing NaH (60%, 3.2 mg) washed with pentane and dried, the same precursor **10** (10 mg) dissolved in 200 µL of DMF-d<sub>7</sub> was added at 0 °C and the reaction stirred at room temperature for 5 min. The reaction mixture was analyzed by <sup>1</sup>H NMR and mass spectrometry. In addition, the solvent was evaporated under vacuum and the residue dissolved in CD<sub>3</sub>OD for <sup>1</sup>H NMR.

#### Acknowledgments

We thank Dr. Jacek Koziorowski of Herlev University Hospital in Denmark for fruitful discussions. We thank Ms. Chuyan (Alice) Cao of Organic Synthesis Core Facility for her assistance in LC–MS purification of Compounds **7** and **8**. We also thank Dr. Jason Lewis, Mr. Howard Sheh, and Mr. Calvin Lom of the MSKCC Cyclotron Core Facility for <sup>18</sup>F production essential for this work. The authors also thank Dr. Cynthia Jung for valuable assistance with the preparation of the manuscript. This work was supported by NIH grant P01 CA115675 (P.I. John Humm/Clifton Ling), and in part P30 CA 008748-43 (Cancer Center Support Grant).

#### References and notes

- Virkam, D. S.; Zweier, J. L.; Kuppusamy, P. *Antioxid. Redox Signal.* **2007**, *9*, 1745.
- Bache, M.; Kappler, M.; Said, H. M.; Staab, A.; Vordermrrk, D. *Curr. Med. Chem.* **2008**, *15*, 322.
- Vaupel, P.; Mayer, A. *Cancer Metastasis Rev.* **2007**, *26*, 225.
- Ling, C. C.; Humm, J.; Larson, S.; Amols, H.; Fuks, Z.; Leibel, S.; Koutcher, J. A. *Int. J. Radiat. Oncol. Biol. Phys.* **2000**, *47*, 551.
- Schinagl, D. A. X.; Kaanders, J. H. A. M.; Oyen, W. J. G. *Cancer Imaging* **2006**, *6*, S107.
- Beaman, A. G.; Caldwell, N.; Duschinsky, R.; Monclair, N. J.; Tautz, W. P. US Patent 3549653, 1970.
- Chapman, J. D.; Urtasun, R. C. *Cancer* **1977**, *40*, 484.
- Rauth, A. M.; Chin, J.; Marchow, L.; Paciga, J. *Br. J. Cancer Suppl.* **1978**, *3*, 202.
- Anderson, R. F.; Patel, K. B. *Br. J. Cancer* **1979**, *39*, 705.
- Kwock, L.; Gill, M.; McMurry, H. L.; Beckman, W.; Raleigh, J. A.; Joseph, A. P. *Radiat. Res.* **1992**, *129*, 71.
- Raleigh, J. A.; Franko, A. J.; Treiber, E. O.; Lunt, J. A.; Allen, P. S. *Int. J. Radiat. Oncol. Biol. Phys.* **1989**, *12*, 1243.
- Tracy, M.; Kelson, A. B.; Workman, P.; Lewis, A.; Aboagye, E. WO9604249A1, 1996.
- Seddon, B. M.; Maxwell, R. J.; Homess, D. J.; Grimshaw, R.; Raynaud, F.; Tozer, G. M.; Workman, P. *Clin. Cancer Res.* **2002**, *8*, 2323.
- Seddon, B. M.; Payne, G. S.; Simons, L.; Ruddle, R.; Grimshaw, R.; Tan, S.; Turnor, A.; Raynaud, F.; Halbert, G.; Leach, M. O.; Judson, I.; Workman, P. *Clin. Cancer Res.* **2003**, *9*, 5101.
- Papadopolou, M. V.; Ji, M.; Bloomer, W. D. *Anticancer Res.* **2006**, *26*, 3253.
- Chapman, J. D.; Lee, J.; Meeker, B. E. *Int. J. Radiat. Oncol. Biol. Phys.* **1989**, *16*, 911.
- Raleigh, J. A.; Franko, A. J.; Kelly, D. A.; Trimble, L. A.; Allen, P. S. *Magn. Reson. Chem.* **1991**, *22*, 451.
- Prociassi, D.; Claus, F.; Burgman, P.; Koziorowski, J.; Chapman, J. D.; Thakur, S. B.; Matei, C.; Ling, C. C.; Koutcher, J. A. *Clin. Cancer Res.* **2007**, *13*, 3738.
- Ackerstaff, E.; Coman, M.; Carlin, S.; Burke, S.; Zakian, K.; Kotedia, K.; O'Donoghue, J.; Ling, C.; Koutcher, J. In *Proceedings of 17th Scientific Meeting, International Society for Magnetic Resonance in Medicine*, Honolulu, Hawaii, 2009; pp 196.
- Johnström, P.; Stone-Elander, S. *J. Labelled Compd. Pharm.* **1995**, *36*, 537.
- Josse, O.; Labar, D.; Georges, B.; Gregoire, V.; Marchand-Brynaert, J. *Bioorg. Med. Chem.* **2001**, *9*, 665.

22. Satter, M. R.; Martin, C. C.; Oakes, T. R.; Christian, B. F.; Nickles, R. J. *Appl. Radiat. Isot.* **1994**, 45, 1093.
23. Kim, P.; Zhang, L.; Manjunatha, U. H.; Singh, R.; Patel, S.; Jiricek, J.; Keller, T. H.; Boshoff, H. I.; Barry, C. E., III; Dowd, C. S. *J. Med. Chem.* **2009**, 52, 1317.
24. (a) Berridge, M. S.; Sayre, L. M.; Arora, P. K.; Terris, A. H.; Riachi, N. J.; Harik, S. I. *J. Med. Chem.* **1993**, 36, 1284; (b) Mathews, W. B.; Ravert, H. T.; Musachio, J. L.; Frank, R. A.; Rinaldi-Carmona, M.; Barth, F.; Dannals, F. R. *J. Labelled Compd. Radiopharm.* **1999**, 42, 589; (c) Hoyte, R. M.; Zhang, J.-X.; Lerum, R.; Oluyemi, A.; Persaud, P.; O'Connor, C.; Labaree, D. C.; Hochberg, R. B. *J. Med. Chem.* **2002**, 45, 5397; (d) Angelini, G.; Speraza, M.; Shiue, C.-Y.; Wolf, A. P. *J. Chem. Soc., Chem. Commun.* **1986**, 924; (e) Kilbourn, M. R.; Pavia, M. R.; Gregor, V. E. *Appl. Radiat. Isot.* **1990**, 41, 823.
25. Itoh, H.; Nitta, A.; Tanaka, T.; Kamio, H.; Tsuboi, K. Eur. Patent 0150842A1, 1985.
26. DePuy, C. H.; Bishop, C. A. *J. Am. Chem. Soc.* **1960**, 82, 2532.
27. Koch, H. F.; Tumas, W.; Knoll, R. J. *Am. Chem. Soc.* **1981**, 103, 5423.
28. Koch, H. F.; Dahlberg, D. B.; McEntee, M. F.; Klecha, C. J. *J. Am. Chem. Soc.* **1976**, 98, 1060.
29. Miller, W. T., Jr.; Fainberg, A. H. *J. Am. Chem. Soc.* **1957**, 79, 4164.
30. Hine, J.; Ghirardelli, R. G. *J. Org. Chem.* **1958**, 23, 1550.
31. Bodor, N.; Huang, M.-J. *Tetrahedron* **1992**, 48, 5823.
32. (a) Aigbirhio, F. I.; Pike, V. W.; Waters, S. L.; Tanner, R. J. N. *J. Fluorine Chem.* **1995**, 70, 279; (b) Pike, V. W.; Waters, S. L.; Aigbirhio, F. I.; Makepeace, J.; Tanner, R. J. N. *Org. Mass Spectrom.* **1994**, 29, 499.
33. (a) Nakai, T.; Tanaka, K.; Ishikawa, N. *J. Fluorine Chem.* **1977**, 9, 89; (b) Tarrant, P.; Young, J. A. *J. Am. Chem. Soc.* **1953**, 75, 932; (c) Wu, K.; Chen, Q.-Y. *Tetrahedron* **2002**, 58, 4077.
34. Depuy, C. H.; Froemsdorf, D. M. *J. Am. Chem. Soc.* **1957**, 79, 3710.
35. Fraser, G. M.; Hoffman, H. M. R.; Ramsay, W.; Forster, R. J. *Chem. Soc.* **1967**, 425.
36. Fekner, T.; Gallucci, J.; Chan, M. K. *Org. Lett.* **2003**, 5, 4795.
37. Wyss, M. T.; Honer, M.; Schubiger, P. A.; Ametamey, S. M. *Eur J Nucl Med Mol Imaging* **2006**, 33, 311.
38. Peterson, I. M.; Muzi, M.; Adamsen, T. C. H.; Link, J. M.; Rajendran, J. G.; Spence, A. M.; Scharnhorst, J.; Krohn, K. A. *J. Labelled Comp. Radiopharm.* **2007**, 50, S423.
39. Workman, P.; Newman, H. F. V.; Beechen, N. M.; Ward, R.; Smithen, C. E. *Cancer Chemother. Pharmacol.* **1991**, 28, 118.
40. Brey, M. L.; Tarrant, P. J. *Am. Chem. Soc.* **1957**, 79, 6533.
41. Miyashita, N.; Yoshikoshi, A.; Grieco, P. A. *J. Org. Chem.* **1977**, 42, 3772.